Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. (0K1R.L) Company Profile & Overview
Explore Viridian Therapeutics, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Viridian Therapeutics, Inc. (0K1R.L) Company Profile & Overview
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.